Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pritumumab

Next Previous
Drug Profile

Pritumumab

Alternative Names: ACA 11; CLN-IgG; CLNH 11; Monoclonal antibody ACA 11

Latest Information Update: 25 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Nascent Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma
  • Preclinical Pancreatic cancer

Most Recent Events

  • 01 Jan 2018 Preclinical trials in Pancreatic cancer in USA (IV)
  • 19 Jul 2016 Nascent Biotech enters into an exclusive licensing agreement with Zhejiang Hisun Pharmaceutical Company for development, manufacture and commercialisation of pritumumab in China
  • 25 Apr 2016 Pritumumab receives Orphan Drug status for Pancreatic cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top